Recital 4, Regulation (EU) 2020/421

In forcesince 18 Mar 2020

Furthermore, an extension of the approval period is prescribed for the active substances dichlorprop-P, mepanipyrim, spinosad, trinexapac and fosetyl, to allow the necessary time to carry out the assessment relating to endocrine disrupting properties in accordance with the procedure set out in Articles 13 and 14 of Implementing Regulation (EU) No 844/2012.

  • celex=32012R0844